Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Holdings Lifted by Hsbc Holdings PLC

Hsbc Holdings PLC increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 49.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,344 shares of the specialty pharmaceutical company’s stock after acquiring an additional 15,041 shares during the period. Hsbc Holdings PLC owned about 0.07% of Jazz Pharmaceuticals worth $4,894,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of JAZZ. Rise Advisors LLC increased its stake in shares of Jazz Pharmaceuticals by 2,255.6% in the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 203 shares during the last quarter. Versant Capital Management Inc increased its position in Jazz Pharmaceuticals by 13,450.0% in the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 269 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Jazz Pharmaceuticals by 65.5% during the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock worth $31,000 after purchasing an additional 116 shares in the last quarter. Cape Investment Advisory Inc. lifted its holdings in shares of Jazz Pharmaceuticals by 14,600.0% during the 4th quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after buying an additional 292 shares during the last quarter. Finally, Gladius Capital Management LP acquired a new stake in shares of Jazz Pharmaceuticals during the 2nd quarter valued at about $33,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Up 0.1 %

JAZZ stock opened at $109.08 on Wednesday. Jazz Pharmaceuticals plc has a twelve month low of $99.06 and a twelve month high of $137.38. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The company has a market cap of $6.88 billion, a PE ratio of 22.49, a price-to-earnings-growth ratio of 1.31 and a beta of 0.57. The business’s 50-day simple moving average is $110.96 and its 200 day simple moving average is $110.89.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share for the quarter, topping the consensus estimate of $3.80 by $0.87. The company had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. On average, research analysts anticipate that Jazz Pharmaceuticals plc will post 16.03 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have issued reports on JAZZ shares. Robert W. Baird reduced their target price on shares of Jazz Pharmaceuticals from $160.00 to $154.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. StockNews.com raised shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. The Goldman Sachs Group started coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 target price on the stock. Royal Bank of Canada decreased their price target on Jazz Pharmaceuticals from $175.00 to $174.00 and set an “outperform” rating for the company in a research note on Thursday, August 1st. Finally, UBS Group dropped their price target on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research report on Tuesday, July 2nd. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $173.07.

Insider Activity

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $108.30, for a total transaction of $152,703.00. Following the sale, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Corporate insiders own 4.20% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.